Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) Times Interest Earned (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Times Interest Earned for 8 consecutive years, with -$1379.6 as the latest value for Q1 2026.

  • For Q1 2026, Times Interest Earned fell 33.46% year-over-year to -$1379.6; the TTM value through Mar 2026 reached -$1006.0, up 8.89%, while the annual FY2025 figure was -$944.32, 10.13% up from the prior year.
  • Times Interest Earned hit -$1379.6 in Q1 2026 for Kymera Therapeutics, down from -$1087.7 in the prior quarter.
  • Across five years, Times Interest Earned topped out at -$371.38 in Q4 2023 and bottomed at -$1402.7 in Q3 2023.
  • Average Times Interest Earned over 5 years is -$986.55, with a median of -$944.09 recorded in 2025.
  • Year-over-year, Times Interest Earned soared 43.28% in 2023 and then plummeted 268.55% in 2024.
  • Kymera Therapeutics' Times Interest Earned stood at -$654.75 in 2022, then skyrocketed by 43.28% to -$371.38 in 2023, then tumbled by 268.55% to -$1368.7 in 2024, then increased by 20.53% to -$1087.7 in 2025, then dropped by 26.83% to -$1379.6 in 2026.
  • According to Business Quant data, Times Interest Earned over the past three periods came in at -$1379.6, -$1087.7, and -$944.09 for Q1 2026, Q4 2025, and Q3 2025 respectively.